Biotech company 10x Genomics filed two lawsuits against rival Illumina in Delaware federal court on Tuesday, accusing ...
Illumina is rated a BUY as it drives growth with AI, multiomics, and strategic acquisitions. Click here to read my earnings ...
The Broad Institute gene-sequencing lab used Roche equipment to read infants’ DNA genomes in less than four hours, cutting an ...
The company's multi-year strategy involves the rollout of new products and upgrades to existing ones that further strengthen its position.
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx .
The company shared pilot data about its Constellation tech and released 5-Base, a product for jointly analyzing genetic and epigenetic data.
Genedx LLC partnered with Illumina Inc. to test whether Illumina's constellation map read technology could shed light on hard ...
Unlike conventional methylation conversion technologies, Illumina's proprietary conversion chemistry selectively converts methylated cytosine to thymine. This selective conversion of methylated ...
Illumina Inc. (NASDAQ:ILMN) has agreed to pay $9.8 million to resolve allegations it knowingly sold genomic sequencing systems with cybersecurity vulnerabilities to several U.S. government agencies.
The U.S. Department of Justice announced July 31 that Illumina Inc. agreed to pay $9.8 million to settle allegations it sold genomic sequencing equipment that suffered from cybersecurity problems. The ...
Illumina exceeded Q2FY25 expectations and raised FY25 guidance, driven by resilient Chinese operations and strong clinical market growth, especially in oncology. The company is expanding into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback